Friday, Mar 01, 2024

Newly-launched U.S. drugs head toward record-high prices in 2022

Newly-launched U.S. drugs head toward record-high prices in 2022

Drugmakers are launching new medicines at record-high prices this year, a Reuters analysis has found, highlighting their pricing power even as Congress moves to cut the $500 billion-plus annual bill for prescription drugs in the United States.

At the same time, some pharmaceutical manufacturers are disclosing less information about the pricing of those treatments, which have come under greater scrutiny in recent years, Reuters found.

"In the U.S. we allow drug manufacturers to freely set prices for all brand-name drugs," Dr. Aaron Kesselheim, professor of medicine at Harvard Medical School and Brigham and Women’s Hospital, told Reuters.

The median annual price of 13 novel drugs approved for chronic conditions by the U.S. Food and Drug Administration so far this year is $257,000, Reuters found.

They were in good company: seven other newly-launched drugs were priced above $200,000. Three other drugs launched in 2022 are used only intermittently and were not included in the calculation.

Last year, the median annual price rose to $180,000 for the 30 drugs first marketed through mid-July 2021, according to a study published recently in JAMA.

While the Reuters tally does not completely replicate the work of that study, it shows that the direction of new drug prices continues to be on the rise.

The JAMA study also excluded drugs that are used intermittently. It included an adjustment for the fact that drugs for very rare diseases have higher prices, which Reuters did not.

The pharmaceutical industry says that prices for new drugs, many of which now treat rare diseases for which there are no therapies, reflect their value to patients, including the ability to prevent costly emergency room visits and hospital stays.

Drugmakers also stress that they do not determine what U.S. patients end up paying for the medicines.

"Each person’s individual (health) insurer and plan will determine the out-of-pocket costs," Eli Lilly & Co said in response to a question about the $12,700 annual price of its new diabetes drug Mounjaro, adding that the company offers savings cards to reduce those costs to as little as $25 a month.


At the same time, drug price information has become harder to confirm. Reuters requested price data from all 15 of the companies that launched new drugs this year.

Six of the manufacturers either did not respond to a request for price details or initially provided only partial information, such as a "per vial" cost, rather than an annual cost based on average patient use, as they had in the past.

Sanofi (SASY.PA) said its new drug Enjaymo, used to treat a rare type of anemia, was priced at $1,800 per vial. When pressed further, the French healthcare group clarified that the typical annual price is $280,800.

Immunocore (IMCR.O) initially disclosed only a "per vial" price for melanoma drug Kimmtrak, and Dermavant Sciences gave only a "per tube" price for its new psoriasis cream. Bristol Myers Squibb (BMY.N) quoted a "per infusion" price for cancer treatment Opdualag. All three eventually provided annual prices.

CTI BioPharma (CTIC.O) referred Reuters to a third-party database, but later gave a monthly price for its rare anemia treatment Vonjo. Mycovia Pharmaceuticals said that "as a private company" it would not provide information on the price of its antifungal drug Vivjoa.

Dr. Ameet Sarwaptwari, a Harvard University professor who specializes in healthcare law, said such incomplete disclosure could be “an attempt to distract” from high annual costs.

Some drugmakers, in response, say treatment costs can vary depending on patient weight and other factors, complicating the estimation of prices for an average patient.

Congress last week passed the landmark $430 billion Inflation Reduction Act that includes a cap on annual drug price increases and allows the Medicare health program for seniors to negotiate prices for up to 20 of the drugs on which it spends the most.

The bill, however, does not limit what drugmakers can charge for new drugs. Some industry experts say that could leave manufacturers even more reliant on higher launch prices.

"The industry will turn to new drugs to try to use the lever that remains uncontrolled," said Daniel Ollendorf, of the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center.

The JAMA-published study on drug prices showed that between 2008 and 2021, U.S. drug launch prices grew 20% annually.

On a net basis, which accounts for volume-based rebates and other discounts that health insurers negotiate with drugmakers, prices for new drugs rose by 11% a year, according to the study led by researchers from the Boston-based Program on Regulation, Therapeutics, and Law and from Brigham and Women’s Hospital.

Reuters did not calculate a comparable rise for 2022 as such discounts are not made public.

Discounts and rebates are often demanded by payers for new drugs once competing treatments become available. As patents expire, lower-cost generics also mitigate prescription drug price inflation, which in the 12 months through July has grown by 2.8%, according to the Bureau of Labor Statistics.

"The vast majority of drugs that Americans use are generics," said Rena Conti, associate professor at Boston University's business school. Drugs for diseases with few treatment options command the highest prices, she said.


Oh ya 2 year ago
On the bright side this might cure some of the millions of people who are too lazy to change there unhealthy lifestyle and rely on drugs to keep them alive as they eat their McRot burgers and such


Related Articles

Apple warns against drying iPhones with rice
In a recent High Court hearing, the U.S. argued that Julian Assange endangered lives by releasing classified information.
Global Law Enforcement Dismantles Lockbit Ransomware Operation
Russian opposition leader Alexey Navalny has died at the Arctic prison colony
The President of Argentina Javier Mile does not fly private, he flies commercial, with the citizens he represents. And they LOVE him for it.
Bitcoin Reaches $50,000 for First Time in Over Two Years
Belo Horizonte: Brazil's Rising Carnival Hotspot for 2024
In El Salvador, the 'Trump of Latin America' stuns the world with a speech slamming woke policing after winning a landslide election
Tucker’s interview with Putin is over 50M views on X within the first 5 hours.
Finnish Airline, Finnair, is voluntarily weighing passengers to better estimate flight cargo weight
President Nayib Bukele has proudly announced El Salvador's remarkable achievement of becoming the safest nation in the Western Hemisphere.
Former Chilean President Sebastian Piñera Dies in Helicopter Crash
This farmer seems to understand science a bit more than the event organizer, Klaus Schwab.
Facebook turns 20: From Mark Zuckerberg's dormitory to a $1trn company
The Coolest Dictator in the World" on the Path to Victory in El Salvador
Macron, France and fake news
Indian-Origin Man 'King' Arrested For Smuggling $16 Million Drugs Into US
Can someone teach Americans that not every person with slanted eyes is Chinese?
Europe's Farmers Feeding the People, Protesting Against Politicians Who Do Nothing for Their Country and Serve Only Themselves at Taxpayers' Expense
Paris Restaurant That Inspired 'Ratatouille' Loses $1.6 Million Worth Of Wine
Brazilian Police Investigate Bolsonaro's Son for Alleged Illegal Spying
Police in Brazil Raid Residence of Bolsonaro Associate Over Allegations of Illegal Spying
Border Dispute Escalates as Texas Governor Vows Increased Razor Wire
OpenAI Enhances ChatGPT-4 Model, Potentially Addressing AI "Laziness" Issue
The NSA finally acknowledges spying on Americans by acquiring sensitive data
Report Reveals Toxic Telegram Group Generating X-Rated AI-Generated Fake Images of Taylor Swift
US Border Patrol States 'No Plans' to Remove Razor Wire Installed in Texas
Bitcoin Experiences Approximately 20% Decline in Value
Klaus Schwab recently appointed himself as the Earth's "trustee of the future."
DeSantis Drops Out, Endorses Trump.
Nikki Haley said former President Trump is "just not at the same level" of mental fitness as he was while president in 2016.
Residents of a southern Mexican town set the government palace on fire in response to the police killing of a young man
Samsung Launches AI-Driven Galaxy S24, Ushering in New Smartphone Era
Judge Questions SEC's Regulatory Overreach in Coinbase Lawsuit
The Ecuador prosecutor who was investigating the television studio attack, has been assassinated.
Is artificial intelligence the solution to cyber security threats?
Vivek Ramaswamy suspends his US election campaign and endorses Trump.
Viral Satire: A Staged Satirical Clip Mistaken as Real Footage from the 2024 World Economic Forum in Davos
The AI Revolution in the Workforce: CEOs at Davos Predict Major Job Cuts in 2024
Ecuador Reports 178 Hostages in Prison Gang Standoff
The Startling Cuban Espionage Case That Has Rattled the US Government
Two Armed Men in Ecuador, Dressed as Batman and The Joker Storm the Streets.
Armed Gang Raids Ecuadorian TV Station Following State of Emergency Declaration
Anti-Democratic Canada: Journalist Arrested for Questioning Canadian Finance Minister on Support of Terrorist Group
Ecuador's 'Most-Wanted' Criminal Vanishes from Prison
Mexican Cartel Supplied Wi-Fi to Locals Under Threat of Fatal Consequences for Non-Compliance
Border Surge Leads to Over 11,000 Migrants Waiting in Northern Mexico
Outsider Candidates Triumph in Latin American Elections
As Argentina Goes to the Polls, Will the Proposal to Replace the Peso with the Dollar Secure Votes?
Fatal Shark Attack Claims Life of Boston Woman Paddleboarding Near Bahamas Resort, According to Police